Investors & Media

Dedicated to delivering long-term investment value.

Hero Investors2

At uniQure, the dual potential for life-changing gene therapies and long-term investor returns creates a unique—and uniquely exciting—opportunity.

Stock Information

Updated stock ticker information for uniQure

  • Price:
  • Change:
  • Volume:

(Updated every 15 minutes)

Learn More

SEC Filings

Security and exchange commission filings for uniQure, including quarterly and annual reports

Learn More


Links to key uniQure corporate governance documents

Learn More

Upcoming Webcasts

No webcasts scheduled. Check back soon.

Webcast Archive

  • uniQure’s Virtual Research & Development Event
    8:30AM ET to 10:30 AM ET

    View Webcast
See All

Investor Presentations

  • Virtual Research & Development Event – Nov. 29 event focused on preclinical gene therapy candidate for refractory temporal lobe epilepsy (rTLE) AMT-260 and uniQure AAV manufacturing advancements

    View Presentation
  • AMT-130 12-Month Low-Dose Cohort Update – Investor Webcast Presentation

    View Presentation
  • ESGCT 2022 – Enhancing efficacy and specificity of AAV5 capsid via small, intermediate, and large peptide insertions

    View Presentation
  • EAHAD 2022 – Final Analysis from the Pivotal Phase 3 HOPE-B Gene Therapy Trial: Stable Steady-State Efficacy and Safety of Etranacogene Dezaparvovec in Adults with Severe or Moderately Severe Hemophilia B

    View Presentation
  • ESGCT 2022 – linQURE™ platform: Development of novel scaffolds for multi-transcript targeting towards the treatment of complex genetic disorders

    View Presentation
See All
uniQure Logo Twitter Icon LinkedIn Icon YouTube Icon Twitter Icon Arrow Slideshow Next Button